Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05519007 · ClinicalTrials.gov registry record · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
A NA study of Joint Infection, sponsored by Northwell Health.
- Recruiting
- Registry status
- NA
- Development phase
- 936
- Enrollment target
- 3
- Study locations
NCT05519007: Recruiting NA study of Joint Infection, sponsored by Northwell Health.
NCT05519007 is a NA study of Joint Infection that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 936 participants, above the 263-participant average among 6 other Joint Infection trials with a reported enrollment target (256% higher). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05519007, a NA study of Joint Infection, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 936 participants
- Enrollment target
- 3
- Study locations
Study Summary
A prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of Next Science No-Rinse Solution (hereby referred to as NS) vs SOC (saline irrigation). The Next Science treatment arm will exhibit greater reduction in rate of 90-day post-operative joint infection than SOC (saline) arm
Primary Outcome
Joint infection rate after surgery
Conditions Studied
Interventions
- OTHER No-Rinse Solution (NS)
- OTHER Saline irrigation
Study Locations (3)
New York
- North Shore University Hospital - Manhasset
- Long Island Jewish Medical Center - New Hyde Park
- Lenox Hill Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 936 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05519007 shows while recruiting
NCT05519007 is an interventional study that assigns participants to a tested intervention. The registered 936 participants enrollment target is mid-sized for trials with a published cap, above the 263-participant average among 6 other Joint Infection trials with a reported enrollment target (256% higher).
The record links to 1 condition, with Joint Infection appearing as the primary indexed condition, and to 2 interventions - of which No-Rinse Solution (NS) is the first listed.
NCT05519007 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05519007 about?
NCT05519007 is a clinical study titled "Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone". A prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of Next Science No-Rinse Solution (hereby referred to as NS) vs SOC (saline irrigatio...
What is the current status of trial NCT05519007?
This trial is currently recruiting. It is a NA study. The enrollment target is 936 participants. The study started on 2023-09-26. Estimated completion is 2026-12-31.
What conditions does trial NCT05519007 study?
This clinical trial studies the following conditions: Joint Infection.
What interventions are being tested in trial NCT05519007?
The interventions under investigation include: No-Rinse Solution (NS) (OTHER), Saline irrigation (OTHER).
Who is sponsoring clinical trial NCT05519007?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05519007 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Joint Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
RECRUITING · NA
-
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
RECRUITING · NA
-
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
ACTIVE NOT RECRUITING · Phase 2
-
Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
COMPLETED
-
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
COMPLETED · Phase 1
-
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- NCT06808334 · 942 participants
CLAiR Pivotal Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI